These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pre-clinical immunogenicity and anti-tumour efficacy of a deleted recombinant human papillomavirus type 16 E7 protein. Hallez S, Brulet JM, Vandooren C, Maudoux F, Thomas S, Heinderickx M, Bollen A, Wattiez R, Jacquet A. Anticancer Res; 2004; 24(4):2265-75. PubMed ID: 15330171 [Abstract] [Full Text] [Related]
6. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Préville X, Ladant D, Timmerman B, Leclerc C. Cancer Res; 2005 Jan 15; 65(2):641-9. PubMed ID: 15695409 [Abstract] [Full Text] [Related]
9. Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Franconi R, Di Bonito P, Dibello F, Accardi L, Muller A, Cirilli A, Simeone P, Donà MG, Venuti A, Giorgi C. Cancer Res; 2002 Jul 01; 62(13):3654-8. PubMed ID: 12097270 [Abstract] [Full Text] [Related]
10. Anti-cancer activity of plant-produced HPV16 E7 vaccine. Massa S, Franconi R, Brandi R, Muller A, Mett V, Yusibov V, Venuti A. Vaccine; 2007 Apr 20; 25(16):3018-21. PubMed ID: 17280752 [Abstract] [Full Text] [Related]
11. Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules. Li H, Ou X, Xiong J. Gynecol Oncol; 2007 Mar 20; 104(3):564-71. PubMed ID: 17081598 [Abstract] [Full Text] [Related]
12. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Eiben GL, Velders MP, Schreiber H, Cassetti MC, Pullen JK, Smith LR, Kast WM. Cancer Res; 2002 Oct 15; 62(20):5792-9. PubMed ID: 12384540 [Abstract] [Full Text] [Related]
17. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor. Jin HS, Park EK, Lee JM, NamKoong SE, Kim DG, Lee YJ, Jun HJ, Han BD, Bae SM, Ahn WS. Gynecol Oncol; 2005 May 15; 97(2):559-67. PubMed ID: 15863160 [Abstract] [Full Text] [Related]
19. Fusion of a tumour-associated antigen to HIV-1 Tat improves protein-based immunotherapy of cancer. Giannouli C, Brulet JM, Gesché F, Rappaport J, Burny A, Leo O, Hallez S. Anticancer Res; 2003 May 15; 23(4):3523-31. PubMed ID: 12926102 [Abstract] [Full Text] [Related]
20. Recombinant human papillomavirus type 16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic mice. Gérard CM, Baudson N, Kraemer K, Ledent C, Pardoll D, Bruck C. Clin Cancer Res; 2001 Mar 15; 7(3 Suppl):838s-847s. PubMed ID: 11300481 [Abstract] [Full Text] [Related] Page: [Next] [New Search]